Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given a consensus rating of “Buy” by the fourteen ratings firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $63.71.

A number of equities research analysts have recently commented on the company. Janney Montgomery Scott downgraded Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Credit Suisse Group reiterated an “outperform” rating and set a $61.00 price objective on shares of Agios Pharmaceuticals in a research report on Tuesday, April 18th. Finally, Zacks Investment Research downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 18th.

In related news, insider Scott Biller sold 4,292 shares of the stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $55.00, for a total transaction of $236,060.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lewis Clayton Jr. Cantley sold 3,500 shares of the stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $56.14, for a total value of $196,490.00. Following the sale, the director now owns 86,697 shares of the company’s stock, valued at $4,867,169.58. The disclosure for this sale can be found here. Insiders sold 31,974 shares of company stock valued at $1,709,236 in the last 90 days. Corporate insiders own 10.55% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Aperio Group LLC purchased a new stake in shares of Agios Pharmaceuticals during the second quarter valued at about $206,000. Creative Planning raised its stake in shares of Agios Pharmaceuticals by 1.4% in the second quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 228 shares in the last quarter. Handelsinvest Investeringsforvaltning purchased a new stake in shares of Agios Pharmaceuticals during the second quarter valued at about $1,492,000. Handelsbanken Fonder AB raised its stake in shares of Agios Pharmaceuticals by 412.5% in the second quarter. Handelsbanken Fonder AB now owns 102,500 shares of the biopharmaceutical company’s stock valued at $5,274,000 after buying an additional 82,500 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Agios Pharmaceuticals by 748.0% in the first quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock valued at $37,909,000 after buying an additional 572,579 shares in the last quarter. Institutional investors and hedge funds own 84.22% of the company’s stock.

Agios Pharmaceuticals (NASDAQ AGIO) traded up 3.03% during trading on Monday, hitting $58.90. The stock had a trading volume of 93,589 shares. The firm’s 50-day moving average price is $53.35 and its 200-day moving average price is $50.13. The stock’s market cap is $2.84 billion. Agios Pharmaceuticals has a 1-year low of $35.84 and a 1-year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.24. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The company had revenue of $10.51 million during the quarter, compared to the consensus estimate of $9.65 million. During the same quarter in the prior year, the firm earned ($0.64) EPS. The company’s quarterly revenue was down 66.4% compared to the same quarter last year. On average, equities research analysts predict that Agios Pharmaceuticals will post ($6.44) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/24/agios-pharmaceuticals-inc-agio-given-average-rating-of-buy-by-brokerages-2.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.